CHM and Parkinson disease: Compared to conventional treatment, CHM paratherapy significantly improved UPDRS II scores (WMD −2.18, 95% CI −3.03 to −1.33; Z = 5.03 (P < 0.001)), suggesting that CHM paratherapy could contribute to improving the activities of daily life (ADLs) in patients with PD (Table 5).